CN100415719C - 2,5-二取代的3-巯基戊酸 - Google Patents
2,5-二取代的3-巯基戊酸 Download PDFInfo
- Publication number
- CN100415719C CN100415719C CNB038138409A CN03813840A CN100415719C CN 100415719 C CN100415719 C CN 100415719C CN B038138409 A CNB038138409 A CN B038138409A CN 03813840 A CN03813840 A CN 03813840A CN 100415719 C CN100415719 C CN 100415719C
- Authority
- CN
- China
- Prior art keywords
- methyl
- aminopyridin
- phenyl
- acid
- mercapto
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE02018372 | 2002-06-14 | ||
| SE0201837A SE0201837D0 (sv) | 2002-06-14 | 2002-06-14 | Chemical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1662504A CN1662504A (zh) | 2005-08-31 |
| CN100415719C true CN100415719C (zh) | 2008-09-03 |
Family
ID=20288202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB038138409A Expired - Fee Related CN100415719C (zh) | 2002-06-14 | 2003-06-10 | 2,5-二取代的3-巯基戊酸 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7572817B2 (enExample) |
| EP (1) | EP1532111B1 (enExample) |
| JP (1) | JP2005533064A (enExample) |
| KR (1) | KR20050010051A (enExample) |
| CN (1) | CN100415719C (enExample) |
| AR (1) | AR040240A1 (enExample) |
| AT (1) | ATE369342T1 (enExample) |
| AU (1) | AU2003241260B2 (enExample) |
| BR (1) | BR0311384A (enExample) |
| CA (1) | CA2488606A1 (enExample) |
| CY (1) | CY1107753T1 (enExample) |
| DE (1) | DE60315471T2 (enExample) |
| DK (1) | DK1532111T3 (enExample) |
| ES (1) | ES2289297T3 (enExample) |
| IS (1) | IS7609A (enExample) |
| MX (1) | MXPA04012604A (enExample) |
| MY (1) | MY160429A (enExample) |
| NO (1) | NO20045051L (enExample) |
| NZ (1) | NZ536814A (enExample) |
| PL (1) | PL373883A1 (enExample) |
| PT (1) | PT1532111E (enExample) |
| RU (1) | RU2365583C2 (enExample) |
| SA (1) | SA03240142B1 (enExample) |
| SE (1) | SE0201837D0 (enExample) |
| TW (1) | TW200401766A (enExample) |
| UA (1) | UA78042C2 (enExample) |
| WO (1) | WO2003106420A1 (enExample) |
| ZA (1) | ZA200409955B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7276497B2 (en) * | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| GB0403864D0 (en) | 2004-02-20 | 2004-03-24 | Ucl Ventures | Modulator |
| JP2008538107A (ja) | 2005-03-18 | 2008-10-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 変異型ｃｆｔｒプロセシングの修正において活性を有する化合物及びその用途 |
| JPWO2010050525A1 (ja) | 2008-10-29 | 2012-03-29 | 大正製薬株式会社 | ＴＡＦＩａ阻害活性を有する化合物 |
| TR201901110T4 (tr) | 2013-04-05 | 2019-02-21 | Boehringer Ingelheim Int | Empagliflozinin terapötik kullanımları. |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN113181161A (zh) | 2013-04-18 | 2021-07-30 | 勃林格殷格翰国际有限公司 | 药物组合物、治疗方法及其用途 |
| BR112015029667A2 (pt) | 2013-06-10 | 2017-07-25 | Sanofi Sa | derivados de ureia macrocíclica como inibidores de tafia, sua preparação e seus usos como produtos farmacêuticos |
| MA46742A (fr) | 2016-11-10 | 2019-09-18 | Boehringer Ingelheim Int | Composition pharmaceutique, méthodes de traitement et leurs utilisations |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000066557A1 (en) * | 1999-05-03 | 2000-11-09 | Astrazeneca Ab | New compounds |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4687500A (en) * | 1999-04-29 | 2000-11-17 | Allergan Sales, Inc. | Thromboxane ligands without blood clotting side effects |
-
2002
- 2002-06-14 SE SE0201837A patent/SE0201837D0/xx unknown
-
2003
- 2003-06-02 AR ARP030101959A patent/AR040240A1/es unknown
- 2003-06-08 SA SA03240142A patent/SA03240142B1/ar unknown
- 2003-06-10 NZ NZ536814A patent/NZ536814A/en unknown
- 2003-06-10 WO PCT/SE2003/000970 patent/WO2003106420A1/en not_active Ceased
- 2003-06-10 KR KR10-2004-7020285A patent/KR20050010051A/ko not_active Ceased
- 2003-06-10 CA CA002488606A patent/CA2488606A1/en not_active Abandoned
- 2003-06-10 DK DK03730987T patent/DK1532111T3/da active
- 2003-06-10 AT AT03730987T patent/ATE369342T1/de not_active IP Right Cessation
- 2003-06-10 PL PL03373883A patent/PL373883A1/xx not_active Application Discontinuation
- 2003-06-10 EP EP03730987A patent/EP1532111B1/en not_active Expired - Lifetime
- 2003-06-10 BR BR0311384-1A patent/BR0311384A/pt not_active IP Right Cessation
- 2003-06-10 RU RU2004134563/04A patent/RU2365583C2/ru not_active IP Right Cessation
- 2003-06-10 MX MXPA04012604A patent/MXPA04012604A/es active IP Right Grant
- 2003-06-10 US US10/517,713 patent/US7572817B2/en not_active Expired - Fee Related
- 2003-06-10 AU AU2003241260A patent/AU2003241260B2/en not_active Ceased
- 2003-06-10 PT PT03730987T patent/PT1532111E/pt unknown
- 2003-06-10 ES ES03730987T patent/ES2289297T3/es not_active Expired - Lifetime
- 2003-06-10 CN CNB038138409A patent/CN100415719C/zh not_active Expired - Fee Related
- 2003-06-10 JP JP2004513253A patent/JP2005533064A/ja not_active Withdrawn
- 2003-06-10 DE DE60315471T patent/DE60315471T2/de not_active Expired - Fee Related
- 2003-06-12 MY MYPI20032192A patent/MY160429A/en unknown
- 2003-06-12 TW TW092115988A patent/TW200401766A/zh unknown
- 2003-10-06 UA UA20041109447A patent/UA78042C2/uk unknown
-
2004
- 2004-11-19 NO NO20045051A patent/NO20045051L/no not_active Application Discontinuation
- 2004-12-08 ZA ZA200409955A patent/ZA200409955B/en unknown
- 2004-12-22 IS IS7609A patent/IS7609A/is unknown
-
2007
- 2007-10-08 CY CY20071101274T patent/CY1107753T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000066557A1 (en) * | 1999-05-03 | 2000-11-09 | Astrazeneca Ab | New compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005533064A (ja) | 2005-11-04 |
| BR0311384A (pt) | 2005-03-15 |
| EP1532111B1 (en) | 2007-08-08 |
| CN1662504A (zh) | 2005-08-31 |
| ES2289297T3 (es) | 2008-02-01 |
| MY160429A (en) | 2017-03-15 |
| AR040240A1 (es) | 2005-03-23 |
| CA2488606A1 (en) | 2003-12-24 |
| ZA200409955B (en) | 2006-08-30 |
| KR20050010051A (ko) | 2005-01-26 |
| PL373883A1 (en) | 2005-09-19 |
| US20050176780A1 (en) | 2005-08-11 |
| TW200401766A (en) | 2004-02-01 |
| SE0201837D0 (sv) | 2002-06-14 |
| WO2003106420A1 (en) | 2003-12-24 |
| US7572817B2 (en) | 2009-08-11 |
| RU2004134563A (ru) | 2005-07-20 |
| MXPA04012604A (es) | 2005-03-23 |
| NO20045051L (no) | 2005-01-13 |
| AU2003241260A1 (en) | 2003-12-31 |
| IS7609A (is) | 2004-12-22 |
| DE60315471T2 (de) | 2008-04-24 |
| HK1077296A1 (en) | 2006-02-10 |
| ATE369342T1 (de) | 2007-08-15 |
| AU2003241260B2 (en) | 2007-04-26 |
| RU2365583C2 (ru) | 2009-08-27 |
| EP1532111A1 (en) | 2005-05-25 |
| SA03240142B1 (ar) | 2007-07-31 |
| UA78042C2 (en) | 2007-02-15 |
| DE60315471D1 (de) | 2007-09-20 |
| DK1532111T3 (da) | 2007-10-22 |
| PT1532111E (pt) | 2007-09-25 |
| CY1107753T1 (el) | 2013-04-18 |
| NZ536814A (en) | 2006-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU675680B2 (en) | Fibrinogen receptor antagonists | |
| AU2003251466B2 (en) | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | |
| MXPA05000697A (es) | Compuestos heteroaromaticos sustituidos con acilamino y su uso como productos farmaceuticos. | |
| CN100415719C (zh) | 2,5-二取代的3-巯基戊酸 | |
| AU2006264051B2 (en) | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals | |
| EP2099753A2 (en) | Heteroarylacrylamides and their use as pharmaceuticals | |
| US8518976B2 (en) | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals | |
| HK1077296B (en) | 2,5-disubstituted 3-mercaptopentanoic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080903 Termination date: 20100610 |